Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LUKE WEBB

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1932161916
CMS profile
314032
Location
COLORADO SPRINGS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$69,181.85

161 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LUKE WEBB

NPI 1932161916 · CMS profile ID 314032

Allopathic & Osteopathic Physicians / Internal Medicine

COLORADO SPRINGS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932161916?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LUKE WEBB, NPI 1932161916, CMS profile ID 314032. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932161916?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). LUKE WEBB, NPI 1932161916, CMS profile ID 314032. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932161916?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
LUKE WEBB, NPI 1932161916, CMS profile ID 314032, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1932161916?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

161 matching records · $69,181.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 161 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 161.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $9.7208/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945164247 CMS
AstraZeneca Pharmaceuticals LP $250.0007/31/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914971795 CMS
AstraZeneca Pharmaceuticals LP $119.8507/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915486029 CMS
Teva Pharmaceuticals USA, Inc. $20.2607/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954733265 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5.5707/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955871739 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.9907/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955871743 CMS
GlaxoSmithKline, LLC. $5.3907/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945164229 CMS
AstraZeneca Pharmaceuticals LP $3,700.0006/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915860359 CMS
GENZYME CORPORATION $17.8406/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938916029 CMS
GlaxoSmithKline, LLC. $5.5506/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945164243 CMS
AstraZeneca Pharmaceuticals LP $3,700.0006/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915043169 CMS
AstraZeneca Pharmaceuticals LP $1,400.0006/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915413593 CMS
AstraZeneca Pharmaceuticals LP $102.5906/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914775993 CMS
AstraZeneca Pharmaceuticals LP $399.6306/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914780955 CMS
AstraZeneca Pharmaceuticals LP $90.0606/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915233259 CMS
AstraZeneca Pharmaceuticals LP $344.1206/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915641577 CMS
AstraZeneca Pharmaceuticals LP $614.2906/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915785401 CMS
AstraZeneca Pharmaceuticals LP $125.0006/16/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915317993 CMS
Genentech USA, Inc. $1.8606/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950771129 CMS
Genentech USA, Inc. $20.3606/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950771131 CMS
Amgen Inc. $131.0206/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939229443 CMS
Amgen Inc. $157.1106/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939229445 CMS
Amgen Inc. $24.0006/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939229447 CMS
Amgen Inc. $16.7806/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939229451 CMS
Amgen Inc. $9.6006/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939229453 CMS
GENZYME CORPORATION $730.0006/01/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938916083 CMS
GENZYME CORPORATION $123.2306/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938916085 CMS
GlaxoSmithKline, LLC. $5.0506/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945164231 CMS
Regeneron Healthcare Solutions, Inc. $16.9006/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927467009 CMS
GlaxoSmithKline, LLC. $5.9505/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945164261 CMS
Grifols USA, LLC $11.2705/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918669321 CMS
Amgen Inc. $3,250.0005/05/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939229439 CMS
Amgen Inc. $3,700.0005/05/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939229449 CMS
AstraZeneca Pharmaceuticals LP $3,250.0005/05/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914790673 CMS
AstraZeneca Pharmaceuticals LP $3,700.0005/05/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915741133 CMS
GlaxoSmithKline, LLC. $21.4705/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945164239 CMS
Amgen Inc. $15.4904/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939229437 CMS
AstraZeneca Pharmaceuticals LP $15.4904/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915803103 CMS
Amgen Inc. $97.4304/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939229441 CMS
AstraZeneca Pharmaceuticals LP $585.4004/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914775603 CMS
AstraZeneca Pharmaceuticals LP $164.6204/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914967141 CMS
AstraZeneca Pharmaceuticals LP $97.4304/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915580085 CMS
AstraZeneca Pharmaceuticals LP $16.7804/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915613291 CMS
AstraZeneca Pharmaceuticals LP $157.1104/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915887273 CMS
kaleo, Inc. $23.9904/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941027743 CMS
BioCryst US Sales Co., LLC $21.9704/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946867911 CMS
AstraZeneca Pharmaceuticals LP $3,700.0004/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915615185 CMS
Aimmune Therapeutics, Inc. $25.8704/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954229475 CMS
GlaxoSmithKline, LLC. $3.6904/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945164237 CMS
Amgen Inc. $570.4004/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939229455 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $46,637.68 101
PY2020 $6,301.54 56
PY2021 $23,392.42 103
PY2022 $69,181.85 161
PY2023 $57,423.17 124
PY2024 $65,677.45 161
PY2025 $18,672.96 96

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $494,431.12 30
PY2024 Principal investigator $118,299.84 32
PY2023 Principal investigator $180,488.28 45
PY2022 Principal investigator $345,323.67 36
PY2021 Principal investigator $207,586.30 26
PY2020 Principal investigator $232,727.42 42
PY2019 Principal investigator $196,413.48 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 12/16/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244045852
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,459.52 12/11/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244045894
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,703.66 11/20/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046154
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $61,864.56 11/13/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046152
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 11/03/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185525
Principal investigator 1 GlaxoSmithKline, LLC. $2,305.00 11/03/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185529
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,631.78 10/30/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046150
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,765.64 10/14/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046148
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $741.00 10/09/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046146
Principal investigator 1 AstraZeneca UK Limited $33,536.00 09/26/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185537655
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 09/18/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046270
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,748.56 09/17/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046144
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,647.72 09/11/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046142
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,130.70 08/21/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046140
Principal investigator 1 GlaxoSmithKline, LLC. $19,300.00 08/01/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185532
Principal investigator 1 GlaxoSmithKline, LLC. $2,788.00 07/28/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187103
Principal investigator 1 GlaxoSmithKline, LLC. $17,019.90 07/28/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187107
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,748.51 07/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046138
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 07/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244045850
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,861.51 06/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046136
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,763.57 05/08/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046336
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,285.14 04/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046334
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 04/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046056
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,243.89 03/20/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046332
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,246.53 03/06/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046330
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/28/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046054
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $19,727.35 02/13/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046328
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,028.33 01/30/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046326
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,040.72 01/16/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046324
Principal investigator 1 Eli Lilly and Company $172,384.33 01/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS No dispute reported 06/30/2026 1187880645